The radioligand therapy (RLT) industry is evolving with major investments from pharmaceutical companies like Eli Lilly and Novartis. These investments are focused on research, manufacturing, and service capabilities to support the adoption of personalized cancer treatments. To succeed in this new landscape, companies must adopt a holistic service approach, prioritize customer centricity, build internal capabilities, integrate services, and establish sustainable funding and governance. By addressing these challenges and evolving their organizational models, companies can lead in the radiopharmaceutical space and drive the widespread adoption of RLT. Leaders like Molly McGaughan and Estelle Ricoux are guiding companies in navigating these changes.
Source link
Unlocking the Future of Radioligand Therapy: From Discovery to Delivering at Scale
